K-Track combines four key analyses—actionable mutations, resistance mutations, germline mutations, and MSI status—with minimal residual disease (MRD) monitoring. It covers 12 cancer types, including NSCLC, breast, liver, stomach, colorectal, ovarian, pancreatic, endometrial, prostate, and esophageal cancers. Both tissue and liquid biopsy are required at the initial test for a complete genomic profile.
Part 1: 14 days actionable, MSI Germline Mutation (upon receipt in lab)
Part 2: 28 days MRD (upon receipt in lab)